CA2662748A1 - Liquid pharmaceutical formulations for oral administration of a cgrp antagonist - Google Patents

Liquid pharmaceutical formulations for oral administration of a cgrp antagonist Download PDF

Info

Publication number
CA2662748A1
CA2662748A1 CA002662748A CA2662748A CA2662748A1 CA 2662748 A1 CA2662748 A1 CA 2662748A1 CA 002662748 A CA002662748 A CA 002662748A CA 2662748 A CA2662748 A CA 2662748A CA 2662748 A1 CA2662748 A1 CA 2662748A1
Authority
CA
Canada
Prior art keywords
oxo
liquid formulation
cremophor
dihydroimidazo
azepan
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002662748A
Other languages
English (en)
French (fr)
Inventor
David Breslin
Joyce Stellabott
Hossain Jahansouz
Laman L. Alani
Karen Thompson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2662748A1 publication Critical patent/CA2662748A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002662748A 2006-09-08 2007-09-06 Liquid pharmaceutical formulations for oral administration of a cgrp antagonist Abandoned CA2662748A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US84305206P 2006-09-08 2006-09-08
US60/843,052 2006-09-08
PCT/US2007/019461 WO2008030524A2 (en) 2006-09-08 2007-09-06 Liquid pharmaceutical formulations for oral administration of a cgrp antagonist

Publications (1)

Publication Number Publication Date
CA2662748A1 true CA2662748A1 (en) 2008-03-13

Family

ID=39157840

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002662748A Abandoned CA2662748A1 (en) 2006-09-08 2007-09-06 Liquid pharmaceutical formulations for oral administration of a cgrp antagonist

Country Status (6)

Country Link
EP (1) EP2063708A2 (zh)
JP (1) JP2010502710A (zh)
CN (1) CN101511184A (zh)
AU (1) AU2007293032A1 (zh)
CA (1) CA2662748A1 (zh)
WO (1) WO2008030524A2 (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2728547A1 (en) * 2008-06-30 2010-01-07 Merck Sharp & Dohme Corp. Solid dosage formulations of telcagepant potassium
CN101756900B (zh) * 2010-02-25 2012-05-30 谢恬 一种榄香烯微乳
EP3915561A1 (en) * 2013-09-16 2021-12-01 Merck Sharp & Dohme Corp. Formulations for cgrp receptor antagonists
WO2015164657A1 (en) * 2014-04-23 2015-10-29 Bcs Business Consulting Services Pte Ltd Incorporation of water soluble component(s) into anhydrous formulations
KR20210151185A (ko) * 2019-04-11 2021-12-13 알.피.쉐러 테크놀러지즈 엘엘씨 난투과성 단백질, 펩타이드 및 소분자의 경구 전달을 위한 제형
WO2023220109A1 (en) * 2022-05-11 2023-11-16 Eli Lilly And Company Glp1 pharmaceutical compositions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6191105B1 (en) * 1993-05-10 2001-02-20 Protein Delivery, Inc. Hydrophilic and lipophilic balanced microemulsion formulations of free-form and/or conjugation-stabilized therapeutic agents such as insulin
JO2355B1 (en) * 2003-04-15 2006-12-12 ميرك شارب اند دوم كوربوريشن Hereditary calcitonin polypeptide receptor antagonists

Also Published As

Publication number Publication date
JP2010502710A (ja) 2010-01-28
WO2008030524A2 (en) 2008-03-13
WO2008030524A3 (en) 2008-10-02
CN101511184A (zh) 2009-08-19
EP2063708A2 (en) 2009-06-03
AU2007293032A1 (en) 2008-03-13

Similar Documents

Publication Publication Date Title
Gullapalli Soft gelatin capsules (softgels)
US20190275006A1 (en) Self-emulsifying pharmaceutical compositions of hydrophilic drugs and preparation thereof
Perlman et al. Development of a self-emulsifying formulation that reduces the food effect for torcetrapib
CN102470103B (zh) 用作丙型肝炎病毒蛋白酶抑制剂的药物组合物
US6306434B1 (en) Pharmaceutical composition comprising cyclosporin solid-state microemulsion
ITMI952411A1 (it) Preparato farmaceutico orale
KR20070084531A (ko) 치환된 아미드의 경구 투여용 액체 및 반고체 약제학적제형
JP2005515996A (ja) 活性型ビタミンｄ化合物を含む薬学的組成物
CZ276995A3 (en) Enhanced pharmaceutical compositions containing alcohol and hydrobhobic medicament
CA2662748A1 (en) Liquid pharmaceutical formulations for oral administration of a cgrp antagonist
SK286967B6 (sk) Spontánne dispergovateľná farmaceutická kompozícia N-benzoylstaurosporínu
DK2575784T3 (en) ORAL DOSAGE FORMS OF BENDAMUSTIN
JP2002538098A (ja) カプセルシステム
Kaushik Recent developments in self-microemulsifying drug delivery system: an overview
Park et al. In vitro and in vivo comparative study of itraconazole bioavailability when formulated in highly soluble self‐emulsifying system and in solid dispersion
CA2662435A1 (en) Liquid and semi-solid pharmaceutical formulations for oral administration of a substituted amide
WO2021055820A1 (en) 3'-[(2z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid and its salts formulation
RU2321404C1 (ru) Фармацевтическая композиция, предназначенная для перорального введения производного пиразол-3-карбоксамида
CN113546044B (zh) 鲁拉西酮自微乳组合物及其制备方法
KR101058860B1 (ko) 수소화 코코-글리세라이드를 이용한 난용성 약물의 자가유화형 나노에멀젼 조성물
CN117771249A (zh) 拉帕替尼自微乳组合物及其制备方法
KR20210090975A (ko) R-치옥트산 또는 이의 약학적으로 허용되는 염, 오일 및 분산보조제를 포함하는 약학조성물

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead
FZDE Dead

Effective date: 20121018